Nightingale Health is a Finnish innovator of blood biomarker testing technology. They have recently announced an expansion beyond its established CE marked blood biomarker service, to offer metabolomics analysis of urine, cerebrospinal fluid (CSF) and umbilical cord blood samples.
These services will deliver comprehensive biomarker data to customers, providing wide-ranging insights into human metabolism and facilitating novel discoveries in biomedical research.
“We are excited to be able to expand our metabolomics offerings in the fall of 2018. Our urine, cerebrospinal fluid (CSF) and umbilical cord blood services will allow us to provide researchers with a pervasive and more complete picture of human health. The ability to compare changes in the metabolic profiles of the different bio-fluids is especially interesting and will further the molecular understanding of health and disease,” said Teemu Suna, CEO of Nightingale.
“Our customers trust their valuable sample collections to be assayed with our technology. The quality standard set by EN ISO 13485 is very demanding, but it also guarantees the analysis and results are of the highest level. Quality is a top priority in medical research, and we believe placing it front and center ensures the reliability of novel scientific findings,” continues Suna.
Nightingale’s expanded capabilities enables the company to fully cater for researchers working on neurodegenerative conditions, kidney diseases, maternal and fetal health, in addition to those already focused on CVD and diabetes.
Nightingale’s current blood biomarker analysis service is built upon a scientific foundation, with over 100 peer-reviewed publications in leading biomedical journals. In 2017, the company achieved recognition that its technology is of a clinical grade standard, receiving CE marking for its blood biomarker analysis service.
The first results from Nightingale’s expanded service will be delivered in the fall, with the company currently taking advanced orders from research institutions worldwide.
Nightingale was established in Helsinki, Finland in 2014 and opened its first laboratory in Kuopio, with €1.4m in funding. In 2015 they received funding from €2.1m from Tekes. They also opened up their first franchising laboratory established in the U.K. In 2016 they were chosen as member of StartUp Health, and secured some €3 million from Cor Group, Nordea, and Finnvera establishing customers in 15 countries with just 12 employees. In 2017, they were one of the winners of the Chronic Disease Challenge by Solve at MIT and the UN and established a second franchising laboratory established at the Oxford University. Customers were then to be found in 20 countries, with 29 employees and nearly 500 000 samples analysed. In 2018 Nightingale was awarded “Health Innovation” of the year!